Results 151 to 160 of about 180,829 (383)
Advanced NanoBiomed Research, EarlyView.This review explains how biomaterials and nanoparticles can be used to induce or modulate tertiary lymphoid structures (TLSs), which are ectopic immune hubs that form in nonlymphoid tissues during chronic disease and cancer. By comparing different methods, the article highlights design principles for modeling TLSs or recapitulating specific TLS ...
Shaza Karaman, Mei ElGindi, Jeremy Teo
wiley +1 more source
Advanced NanoBiomed Research, EarlyView.This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari +5 more
wiley +1 more source
Non-Hodgkin’s Lymphoma of the Uterine Cervix [PDF]
, 2012 Non Hodgkin’s Lymphoma (NHL) causes many deaths worldwide and its incidence is increasing. They occur commonly in middle aged and elderly people and are disseminated at diagnosis.
Kaler, AK, Vasudev, DS
core
Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production [PDF]
, 2017 Natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC), based on the recognition of IgG-opsonized targets by the low-affinity receptor for IgG FcγRIIIA/CD16, represents one of the main mechanisms by which therapeutic antibodies
Battella, Simone +9 more
core +2 more sources
Arthritis &Rheumatology, EarlyView.Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley +1 more source
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden
Haematologica, 2011 Background CD20 monoclonal antibodies are widely used in clinical practice. Antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and direct cell death have been suggested to be important effector functions for CD20 antibodies ...
Peter Boross +10 more
doaj +1 more source
Annus Mirabilis - a guide to the 6th European Lupus meeting 3-5 March 2005 [PDF]
, 2005 This article has no ...
Bowman, S.J. +4 more
core
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. [PDF]
, 2004 BACKGROUND: An open-label study indicated that selective depletion of B cells with the use of rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To confirm these observations, we conducted a randomized, double-blind,
Close, DR +7 more
core +1 more source
Anti-CD20 therapy depletes activated myelin-specific CD8+ T cells in multiple sclerosis
Proceedings of the National Academy of Sciences of the United States of America, 2019 Significance Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system. CD8+ T cells have been strongly implicated in MS pathogenesis, but it is unclear whether myelin is a CD8+ T cell autoantigenic target in MS. This
J. Sabatino +5 more
semanticscholar +1 more source
Arthritis &Rheumatology, EarlyView.Objective The spontaneous K/BxN mouse model of rheumatoid arthritis has been used extensively to study chronic inflammation, contribution of immune cells, and the primordial role of autoreactive antibodies in disease initiation and severity. Only the ubiquitous enzyme glucose‐6‐phosphate isomerase (GPI) is the target of IgG autoantibodies secreted by ...
Thibault Vanhoucke +8 more
wiley +1 more source